ADAR and cancer: Overactivity of ADAR1 can suppress type I interferon responses, contributing to resistance to immune checkpoint blockade therapies in cancer [9], while loss of ADAR1 activity can result in rampant interferon signaling and chronic inflammation in autoimmune contexts [10,11,12,13].